A multicentre, retrospective study to evaluate the role of HLA -C*06 as a pharmacogenetic marker of response to ustekinumab.

Trial Profile

A multicentre, retrospective study to evaluate the role of HLA -C*06 as a pharmacogenetic marker of response to ustekinumab.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2017 New trial record
    • 16 Feb 2017 Primary endpoint has been met (The proportion of patients achieving at least 50% reduction in the PASI score (PASI 50) at week 4.), according to results published in the British Journal of Dermatology.
    • 16 Feb 2017 Results published in the British Journal of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top